Healthcare
Novartis’ gene therapy Zolgensma is again under a cloud of doubt after Nature Biotechnology retracted its 2010 article noting “issues” regarding data cited in a key figure in the report.
Top-line data from the Phase III STELLAR trial revealed that Merck’s activin receptor candidate sotatercept reached its primary endpoint in pulmonary arterial hypertension.
Amylyx plans to offer 6 million shares in a public offering to bring in between $167 to $192.2 million to support the manufacturing and commercialization of recently approved ALS drug Relyvrio.
The HHS Office of Inspector General found that of 278 accelerated approvals between 1992 and 2021, 104 had incomplete confirmatory trials, according to a report issued Thursday.
Novo Nordisk struck a licensing deal Thursday with Ventus Therapeutics valued at up to $700 million to develop and commercialize peripherally-restricted NLRP3 inhibitors.
Merck announced positive results on its patent infringement case against Viatris, while Amgen faces political headwinds from the White House.
Novartis outlined how its transformation to a pure-play innovative medicines company is nearly completed during a “Meet the Management” event in Switzerland.
After enduring nine months of clinical holds, Merck announced that it is restarting the Phase III clinical program for islatravir, its candidate for people with HIV-1 infection.
With 33 approvals from the FDA, Merck’s checkpoint inhibitor Keytruda has become a powerhouse oncology drug and is likely to continue to rack up more regulatory wins.
Industry observers say the Inflation Reduction Act of 2022 could affect the direction of research, and some fear it may lead to further government forays into price control.
PRESS RELEASES